)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Evogene
Evogene (EVGN) investor relations material
Evogene Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary18 Aug, 2026
Executive summary
Underwent a major transformation into a lean, AI-driven computational chemistry leader for pharma and crop protection, reducing headcount from 117 to 38 and cash burn from $20.5M in 2024 to $8.5–$9.5M expected in 2026.
Secured six drug development agreements, completed key milestones in both pharma and ag pipelines, and monetized non-core assets including Lavie Bio and Biomica.
Expanded ChemPass AI platform, integrating advanced AI agents and increasing virtual chemical space to 110 billion molecules.
Board faces a challenge from dissident shareholders but emphasizes continuity, adding two new industry experts to strengthen governance.
Financial highlights
Consolidated cash and equivalents at $9.3M as of June 30, 2026; Q2 cash usage was $2.1M.
Q2 net loss improved to $1.8M from $4.7M in Q2 2025 and $6M in Q2 2024, driven by lower operating expenses and higher financing income.
H1 2026 revenues were $0.7M, down from $2.9M in H1 2025, mainly due to lower Casterra sales.
R&D expenses for H1 2026 were $2.9M, down from $3.5M in H1 2025; Q2 2026 R&D expenses were $1.4M, down from $1.7M in Q2 2025.
Net loss for H1 2026 was $7.7M, unchanged from H1 2025.
Outlook and guidance
Full-year 2026 cash usage expected at $8.5–$9.5M, with further reductions anticipated in 2027.
Focus remains on advancing pharma and ag pipelines, securing new collaborations, and commercializing AI-driven platforms.
Plans to increase investor outreach and IR activities as operational milestones are achieved.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Evogene
- Revenue reached $3.8 million as Casterra scaled seed deliveries and net loss narrowed.EVGN
Q3 2023 - AI-driven platform accelerates multi-parameter small molecule discovery for pharma and ag-chem.EVGNCompany presentation
- Q1 2026 revenue fell to $0.3M and net loss widened as AI-driven pipeline and partnerships advanced.EVGNQ1 2026
- AI-driven small molecule discovery focus, with dilution and volatility risks for shareholders.EVGNRegistration filing
- AI-driven molecular design platform accelerates pharma and ag-chemical innovation and partnerships.EVGNCorporate presentation
- Strategic refocus and cost cuts narrowed net loss to $7.8M despite lower 2025 revenue.EVGNQ4 2025
- ChemPass AI pivot follows lower losses, the ICL sale and new financing.EVGNQ2 2025
- Nine-month revenues reached $6.9M, but Q3 net loss rose to $8.2M on higher expenses.EVGNQ3 2024
- Revenue up, losses down, and H2 growth expected from Casterra seed orders and new products.EVGNQ2 2024
Next Evogene earnings date
Q3 202619 Nov, 2026
Evogene
Next Evogene earnings date
Q3 202619 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Evogene Ltd. is an Israel-based biotechnology company focused on the development of computational biology-based solutions for agriculture, pharmaceuticals, and industrial applications. The company leverages artificial intelligence and big data analytics to discover and develop products in areas such as crop protection, seed traits, microbiome-based solutions, and drug discovery. The company is headquartered in Rehovot, Israel, and its shares are listed on the NASDAQ and TASE.